Mostrar el registro sencillo del ítem
dc.contributor.author
Monti Hughes, Andrea

dc.contributor.author
Hu, Naonori
dc.date.available
2024-06-11T10:09:58Z
dc.date.issued
2023-08
dc.identifier.citation
Monti Hughes, Andrea; Hu, Naonori; Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies; Multidisciplinary Digital Publishing Institute; Cancers; 15; 16; 8-2023; 1-30
dc.identifier.issn
2072-6694
dc.identifier.uri
http://hdl.handle.net/11336/237712
dc.description.abstract
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and StrategiesAndrea Monti Hughes 1 2, Naonori Hu 3 4Affiliations1Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina.2National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina.3Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.4Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan.AbstractBoron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Multidisciplinary Digital Publishing Institute
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
BNCT;
dc.subject
boron neutron capture therapy;
dc.subject
new boron compounds;
dc.subject
radiobiological studies;
dc.subject
strategies;
dc.subject
targeted therapy;
dc.subject
theranostic compounds.
dc.subject.classification
Otras Medicina Básica

dc.subject.classification
Medicina Básica

dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD

dc.title
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-06-07T15:21:31Z
dc.journal.volume
15
dc.journal.number
16
dc.journal.pagination
1-30
dc.journal.pais
Suiza

dc.description.fil
Fil: Monti Hughes, Andrea. Comisión Nacional de Energía Atómica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Hu, Naonori. Osaka Medical and Pharmaceutical University; Japón. Kyoto University; Japón
dc.journal.title
Cancers
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/cancers15164091
Archivos asociados